However, in this case the disease-causing VCP mutation p.Asp395Gly is linked to the aggregation propensity of TAU, as it impairs the TAU disaggregase activity of VCP, making it a potential new therapeutic target for AD and other tauopathies [247]. The gene discussed is VCP; the disease is Alzheimer disease.